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Several studies have shown that loss of expression of the
receptor-interacting serine/threonine protein kinase 3
(RIPK3), an essential mediator of necroptotic cell death,
promotes the development of cancer, including acute
myeloid leukaemia [1]. Moreover, downregulation of
RIPK3 has been associated with the resistance of chronic
lymphocytic leukaemia cells to necroptotic cell death [1].
Here, we studied the impact of loss of RIPK3 in a mouse
model of MYC-driven lymphomagenesis and on the killing
of malignant lymphoma cells induced by chemother-
apeutics. We found that Ripk3 deficiency did not accelerate
lymphoma development in Eμ-Myc transgenic mice.
Moreover, the loss of RIPK3 did not alter the sensitivity of
Eμ-Myc lymphoma cells to chemotherapeutic drugs. These
results reveal that RIPK3 does not play critical roles for the
development of MYC-driven lymphomas or their ther-
apeutic responses.
To examine the impact of the loss of Ripk3 on MYC-
driven lymphomagenesis, we utilised the Eμ-Myc mouse
model. Eμ-Myc;Ripk3−/− mice displayed a median survival
of 97 days (n= 80), which was not significantly different
from the 118 days seen in control Eμ-Myc mice (n= 37)
(Eμ-Myc;Ripk3−/− vs Eμ-Myc mice, p= 0.0944) (Fig. 1a).
At the ethically mandated endpoint, the severity of disease,
as determined by the extent of spleen and lymph node
enlargement and white blood cell counts, was comparable
between mice of the two genotypes (Supplementary Fig. 1a,
b). Immuno-phenotyping revealed that all lymphomas in
Eμ-Myc;Ripk3−/− mice were, as expected, of pro/pre-B
(B220+sIg−) or B (B220+sIg+) origin, although there was
an increased portion of mixed pre-B/B lymphomas com-
pared with the control Eμ-Myc mice (Fig. 1b).
Some other studies have reported that treatment with
chemotherapeutic drugs induces the formation of the
RIPK1/RIPK3/CASPASE-8 ripoptosome complex that
triggers necroptotic cell death and that knockdown of
RIPK3 can inhibit this killing of tumour cells [2–6]. To
assess whether loss of RIPK3 could affect the response of
malignant lymphoma cells to therapeutic agents we made
use of CRISPR/Cas9 technology to generate Eμ-Myc p53
wild-type (AF47A and AH15A) lymphoma cell lines that
are deficient for RIPK3 (Supplementary Fig. 2a, b). The
Ripk3 knockout cells showed similar sensitivity to eto-
poside, paclitaxel or dexamethasone as the control cells,
although some minor differences were observed
(Fig. 1c–e). Similarly, the loss of RIPK3 had no impact on
the response of lung carcinoma, colon carcinoma or thy-
mic lymphoma derived cell lines to a range of che-
motherapeutics [7, 8]. Human and mouse tumour cells
driven by deregulated over-expression of c-MYC are
highly dependent on the anti-apoptotic protein MCL-1 for
survival and the MCL-1-specific BH3 mimetic drug
S63845 induces dose dependent apoptotic death in murine
Eμ-Myc as well as human Burkitt’s lymphoma cell lines
[9, 10]. Loss of RIPK3 did not affect the response of
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Fig. 1 RIPK3 does not play a critical role in the development or
therapeutic response in MYC-driven lymphomas. a Kaplan–Meier
survival curves of Eμ-Myc (n= 37, median survival of 118 days),
Eμ-Myc;Ripk3+/− (n= 54, median survival of 97 days) or Eμ-Myc;
Ripk3−/− (n= 80, median survival of 97 days) mice. The difference in
survival between mice of the different the genotypes was not sig-
nificant (log-rank (Mantel–Cox) test). b Stacked bar graph showing the
percentages of pro/pre-B (B220+sIg−), B (B220+sIg+) and mixed pre-
B/B cell lymphomas observed for Eμ-Myc (n= 34), Eμ-Myc;Ripk3+/−
(n= 6) and Eμ-Myc;Ripk3−/− (n= 13). The difference in surface
marker phenotype between lymphomas of the different genotypes was
not significant (repeated measures one-way ANOVA, with the
Geisser–Greenhouse correction). c–f Eμ-Myc lymphoma cell lines with
wt p53, AF47A and AH15A, transduced with expression constructs
for Cas9 and sgRNAs targeting Ripk3 (RIPK3 KO) or transduced with
an empty vector (EV) were treated with increasing concentrations of
etoposide (0–10 μM) (c), paclitaxel (0–10 μM) (d), dexamethasone
(0–50 μM) (e) for 48 h, or (f) with S63845 (0–10 μM) for 24 h. Cell
viability was assessed using Annexin V plus PI staining and FACS
analysis. The frequency of Annexin V−PI− cells was normalised to
control (DMSO treated) cells (Viability (% untreated)). Means ± SD
for three independent experiments are shown.
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Eμ-Myc lymphoma cell lines to S63845 (Fig. 1f). Staining
with Annexin V and propidium iodide (PI) revealed that
both the parental and the Ripk3-deleted Eμ-Myc lym-
phoma cells showed classical features of apoptosis
(Annexin V+PI−) at early time points after treatment with
chemotherapeutic drugs (Supplementary Fig. 3). Accord-
ingly, loss of the pro-apoptotic effectors BAX and BAK
rendered the Eμ-Myc lymphoma cells completely resistant
to these agents (Supplementary Fig. 3).
Collectively, these findings demonstrate that RIPK3,
and by extension necroptotic cell death, is not a major
suppressor of MYC-driven lymphoma development.
Moreover, the results indicate that RIPK3 and necroptosis
do not play major roles in the response of malignant
lymphoma cells to a range of anti-cancer agents, at least
under tissue culture conditions. As the Eμ-Myc mice
constitute a model of human Burkitt’s lymphoma, it
therefore remains possible that RIPK3 and necroptosis
may play a role in other types of lymphoma or other
malignancies. Moreover, RIPK3 and necroptosis might
play a role in the response of Eμ-Myc lymphomas (and
other tumours) to anti-cancer agents in vivo, perhaps by
impacting anti-tumour immune responses from the host,
and we will make our cell lines available for such
investigations.
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